<?xml version='1.0' encoding='utf-8'?>
<document id="24976448"><sentence text="Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study."><entity charOffset="36-48" id="DDI-PubMed.24976448.s1.e0" text="rosuvastatin" /><entity charOffset="53-62" id="DDI-PubMed.24976448.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24976448.s1.e0" e2="DDI-PubMed.24976448.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s1.e0" e2="DDI-PubMed.24976448.s1.e1" /></sentence><sentence text="Rosuvastatin is indicated for hypercholesterolemia or dyslipidemia and metformin mainly for type 2 diabetes"><entity charOffset="0-12" id="DDI-PubMed.24976448.s2.e0" text="Rosuvastatin" /><entity charOffset="71-80" id="DDI-PubMed.24976448.s2.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24976448.s2.e0" e2="DDI-PubMed.24976448.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s2.e0" e2="DDI-PubMed.24976448.s2.e1" /></sentence><sentence text=" These 2 drugs are frequently prescribed in combination due to the high comorbidity of the 2 diseases" /><sentence text=" However the nature of pharmacokinetic interaction between the 2 drugs has not been previously investigated" /><sentence text=" The purpose of our study was to investigate the pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers"><entity charOffset="85-97" id="DDI-PubMed.24976448.s5.e0" text="rosuvastatin" /><entity charOffset="102-111" id="DDI-PubMed.24976448.s5.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24976448.s5.e0" e2="DDI-PubMed.24976448.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s5.e0" e2="DDI-PubMed.24976448.s5.e1" /></sentence><sentence text="" /><sentence text="This was a randomized, open-label, 6-sequence, 3-period, crossover, multiple-dose study" /><sentence text=" Eligible subjects, aged 20 to 50 years and within 20% of the ideal body weight, received 1 of the following 3 treatments for each period once daily for 5 consecutive days with a 10-day washout period between the treatments: monoadministration of rosuvastatin 10 mg tablet, monoadministration of metformin 750 mg tablet, and coadministration of rosuvastatin 10 mg tablet with metformin 750 mg tablet"><entity charOffset="247-259" id="DDI-PubMed.24976448.s8.e0" text="rosuvastatin" /><entity charOffset="296-305" id="DDI-PubMed.24976448.s8.e1" text="metformin" /><entity charOffset="345-357" id="DDI-PubMed.24976448.s8.e2" text="rosuvastatin" /><entity charOffset="376-385" id="DDI-PubMed.24976448.s8.e3" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e0" e2="DDI-PubMed.24976448.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e0" e2="DDI-PubMed.24976448.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e0" e2="DDI-PubMed.24976448.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e0" e2="DDI-PubMed.24976448.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e1" e2="DDI-PubMed.24976448.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e1" e2="DDI-PubMed.24976448.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e1" e2="DDI-PubMed.24976448.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e2" e2="DDI-PubMed.24976448.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s8.e2" e2="DDI-PubMed.24976448.s8.e3" /></sentence><sentence text=" Blood samples were collected up to 72 hours after the last dose and pharmacokinetic parameters for rosuvastatin and metformin were compared between combination and monotherapy"><entity charOffset="100-112" id="DDI-PubMed.24976448.s9.e0" text="rosuvastatin" /><entity charOffset="117-126" id="DDI-PubMed.24976448.s9.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24976448.s9.e0" e2="DDI-PubMed.24976448.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s9.e0" e2="DDI-PubMed.24976448.s9.e1" /></sentence><sentence text=" Adverse events were investigated and evaluated based on subject interviews and physical examinations" /><sentence text="" /><sentence text="Among the 36 enrolled subjects, 31 completed the study" /><sentence text=" The coadministration of rosuvastatin with metformin produced a significant pharmacokinetic interaction in rosuvastatin Css,max, with the 90% CI for the geometric mean ratio (coadministration:monoadministration) being 110"><entity charOffset="25-37" id="DDI-PubMed.24976448.s13.e0" text="rosuvastatin" /><entity charOffset="43-52" id="DDI-PubMed.24976448.s13.e1" text="metformin" /><entity charOffset="107-119" id="DDI-PubMed.24976448.s13.e2" text="rosuvastatin" /><entity charOffset="142-144" id="DDI-PubMed.24976448.s13.e3" text="CI" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e0" e2="DDI-PubMed.24976448.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e0" e2="DDI-PubMed.24976448.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e0" e2="DDI-PubMed.24976448.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e0" e2="DDI-PubMed.24976448.s13.e3" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e1" e2="DDI-PubMed.24976448.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e1" e2="DDI-PubMed.24976448.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e1" e2="DDI-PubMed.24976448.s13.e3" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e2" e2="DDI-PubMed.24976448.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s13.e2" e2="DDI-PubMed.24976448.s13.e3" /></sentence><sentence text="27% to 136" /><sentence text="39% (P = 0" /><sentence text="0029), whereas no significant interaction was observed in rosuvastatin AUCtau, yielding the 90% CI of 104"><entity charOffset="58-70" id="DDI-PubMed.24976448.s16.e0" text="rosuvastatin" /><entity charOffset="96-107" id="DDI-PubMed.24976448.s16.e1" text="CI" /><pair ddi="false" e1="DDI-PubMed.24976448.s16.e0" e2="DDI-PubMed.24976448.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s16.e0" e2="DDI-PubMed.24976448.s16.e1" /></sentence><sentence text="41% to 118" /><sentence text="95%" /><sentence text=" When metformin was coadministered with rosuvastatin, no significant pharmacokinetic interaction was observed for Css,max and AUCtau of metformin, yielding the 90% CIs of the geometric mean ratio for coadministration to monoadministration as 87"><entity charOffset="6-15" id="DDI-PubMed.24976448.s19.e0" text="metformin" /><entity charOffset="40-52" id="DDI-PubMed.24976448.s19.e1" text="rosuvastatin" /><entity charOffset="136-145" id="DDI-PubMed.24976448.s19.e2" text="metformin" /><entity charOffset="164-172" id="DDI-PubMed.24976448.s19.e3" text="CI" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e0" e2="DDI-PubMed.24976448.s19.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e0" e2="DDI-PubMed.24976448.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e0" e2="DDI-PubMed.24976448.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e0" e2="DDI-PubMed.24976448.s19.e3" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e1" e2="DDI-PubMed.24976448.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e1" e2="DDI-PubMed.24976448.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e1" e2="DDI-PubMed.24976448.s19.e3" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e2" e2="DDI-PubMed.24976448.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24976448.s19.e2" e2="DDI-PubMed.24976448.s19.e3" /></sentence><sentence text="38% to 102" /><sentence text="54% and 86" /><sentence text="70% to 99" /><sentence text="08%, respectively" /><sentence text=" Overall, 19 mild and 1 moderate adverse events occurred in 12 subjects, with no significant differences in the incidence among the 3 treatments" /><sentence text="" /><sentence text="Although the Css,max of rosuvastatin was significantly influenced by coadministration with metformin, the degree of interaction seen was considered clinically insignificant, with no significant interaction observed in the other pharmacokinetic measures between the 2 drugs"><entity charOffset="24-36" id="DDI-PubMed.24976448.s26.e0" text="rosuvastatin" /><entity charOffset="91-100" id="DDI-PubMed.24976448.s26.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24976448.s26.e0" e2="DDI-PubMed.24976448.s26.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s26.e0" e2="DDI-PubMed.24976448.s26.e1" /></sentence><sentence text=" These results imply that drug effects of rosuvastatin and metformin will also not be significantly influenced by coadministration of the 2 drugs"><entity charOffset="42-54" id="DDI-PubMed.24976448.s27.e0" text="rosuvastatin" /><entity charOffset="59-68" id="DDI-PubMed.24976448.s27.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24976448.s27.e0" e2="DDI-PubMed.24976448.s27.e0" /><pair ddi="false" e1="DDI-PubMed.24976448.s27.e0" e2="DDI-PubMed.24976448.s27.e1" /></sentence><sentence text=" All treatments were well tolerated and no serious adverse events occurred" /><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT01526317" /><sentence text="" /></document>